Baseline [18F]FDG PET/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial “watch-and-wait” approach
Author:
Funder
the CAMS Innovation Fund for Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00330-022-08624-7.pdf
Reference30 articles.
1. Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95:316–327
2. Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388–1395
3. Dreyling M, Ghielmini M, Rule S et al (2020) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.11.008
4. Pan Q, Luo Y, Cao X, Zhang Y, Li F (2019) Spontaneous regression of clinically indolent lymphomas revealed by [18F]FDG PET/CT. Clin Nucl Med 44:321–323
5. Luo Y, Zhang Y, Pan Q, Zhang Y, Li F (2020) [18F]FDG PET/computed tomography may predict the outcome of newly diagnosed indolent non-Hodgkin lymphoma in patients managed with initial 'watch-and-wait' approach. Nucl Med Commun 41:1283–1290
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Baseline 18F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma;European Journal of Radiology;2024-09
2. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma;Scientific Reports;2024-04-05
3. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma;Hematological Oncology;2023-11-09
4. PET/CT in Non-Hodgkin Lymphoma: An Update;Seminars in Nuclear Medicine;2023-05
5. Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab;HemaSphere;2023-04-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3